公司发展 - 公司在2022年6月成立了全资金融服务子公司Dominari Financial Inc.，意图将主要经营重点从生物技术转向金融科技和金融服务行业[70] 财务表现 - 在2023年6月30日结束的三个月内，公司从运营中实现了约70万美元的收入，主要来自Dominari Securities的承销收入[78] - 2023年6月30日结束的三个月内，公司的运营亏损约为900万美元，主要原因是一般和行政费用的增加，以及研发费用的减少[78] - 公司的工作资本截至2023年6月30日约为3570万美元，预计现金、现金等价物和市场证券的预期现金流量将足以满足未来至少12个月的工作资本和资本支出需求[88] - 公司在2023年6月30日结束的六个月内，运营活动中的现金使用约为1390万美元，主要是由于净亏损、市场证券的实现收益和运营资产和负债的变化[90] - 在2023年6月30日结束的六个月内，公司的投资活动中的净现金使用约为1470万美元，主要是由于购买市场证券和FPS的收购[91] - 在2023年6月30日结束的六个月内，公司的融资活动中的现金使用约为90万美元，主要是用于购买库存股[93]

公司发展 - 公司在2022年6月成立了全资金融服务子公司Dominari Financial Inc.，意图将主要经营重点从生物技术转向金融科技和金融服务行业[82] 财务状况 - 公司在2023年3月31日的三个月内，未实现任何营业收入，预计在完成向金融服务行业的运营转型之前不会实现任何收入[90] - 2023年3月31日的三个月内，公司的运营亏损约为380万美元，主要原因是一方面由于成立和运营Dominari Financial和Dominari Securities而产生的专业费用增加，另一方面由于公司决定从生物技术行业转向金融服务行业而导致研发费用减少[90] 公司协议 - 公司发布了就业协议和修正协议，涉及到Dominari Securities LLC和Soo Yu[110] 法律合规 - 主管执行官和首席财务官根据Sarbanes-Oxley法案第302条的要求提供了认证[110] - 主管执行官和首席财务官根据Sarbanes-Oxley法案第906条的要求提供了认证[110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 000-05576 DOMINARI HOLDINGS INC. (Exact name of Registrant as specified in its Charter) | Delaware | 52-0849320 | | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 AIKIDO PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 52-0849320 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------------------------------|---------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------|--------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ($0.0001 par value per share) AIKI The NASDAQ Capital Market FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------------------------------------|----- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 AIKIDO PHARMA INC. | --- | --- | |------------------------------------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |-----------------------------------------------------------------------------------| ...